Web11 apr. 2024 · Het onderzoek van Morgan Stanley bevestigt het advies en handhaaft het Neutraal advies voor het aandeel. Het koersdoel is verhoogd en is nu 42 USD ten opzichte van 40 USD voorheen. 11 april 2024 WebAstraZeneca en Ionis heeft het recht het product samen met AstraZeneca in de VS te commercialiseren. Kwartaal nieuwsbrief Aescap Genetics • Arent Janszoon Ernststraat 595C, 1082 LD, Amsterdam, The Netherlands tel. +31(0)20 570 29 40 • www.aescap.com 1 april 2024 Data per 31 maart 2024 . 5
Stephanie Kristin Klein - Director, Pathology - Ionis ... - LinkedIn
Web23 sep. 2024 · In a statement, Ionis said that AZD8233 met its objectives in the phase 2b SOLANO trial in patients with hypercholesterolaemia, when given as a monthly 60mg … Web5 mei 2024 · Ionis reported total revenues of $142 million, up 26.8% year over year due to higher R&D revenues, which made up for lower commercial revenues. Sales beat the Zacks Consensus Estimate of $129.0... grandcamp-maisy tourisme
Kwartaal nieuwsbrief 1 april 2024
Web27 mrt. 2024 · released topline results from the 66-week analysis of Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca Plc's AZN -0.19% + Free Alerts … Web7 dec. 2024 · As part of their agreement, Ionis and AstraZeneca will develop a global strategy for developing, manufacturing and commercializing eplontersen. Ionis will continue to lead the conduct of the global phase 3 clinical trials in patients with (hATTR) with polyneuropathy (NEURO-TTRansform) and cardiomyopathy (CARDIO-TTRansform). Web23 sep. 2024 · AstraZeneca licensed ION449 from Ionis in 2015. About Hypercholesterolemia Hypercholesterolemia, or elevated LDL-C levels in the blood, is an important risk factor for cardiovascular disease,... grandcamp maisy battery